PCAS has announced a net loss for 2022 of -48.8 million euros, compared with -40.5 million in 2021, despite a year-on-year increase in EBITDA from -4.6 to +2.2 million, on sales up 21.1% to 226.4 million (+17.9% at constant exchange rates).

The chemist explains that its results were affected by 'a level of activity still insufficient to cover fixed costs on several sites in pharmaceutical synthesis, as well as by inventory write-downs relating to non-compliant products'.

PCAS indicates that the return to positive results, announced for 2023, has been postponed, but that it 'continues to benefit from the support of its majority shareholder Seqens for the financing of its activities and its development'.

Copyright (c) 2023 CercleFinance.com. All rights reserved.